 |
|
|
| |
Characterization of Virologic Resistance in HCV Genotype 1 Null Responders Receiving a Dual Direct- Acting Antiviral Combination of NS3 Protease Inhibitor Asunaprevir (ASV; BMS-650032) and NS5A Replication Complex Inhibitor Daclatasvir (DCV; BMS-790052) (poster presentation)
|
| |
| |
Reported by Jules Levin
HepDART 2011
Koloa, Hawaii, December 4-8, 2011
F McPhee, D Hernandez, F Yu, J Ueland, R Fridell, C Wang, A Monikowski, N Zhou, S Levine, D Gardiner, E Hughes, H Watanabe, H Ishikawa, H Kumada, M Gao, Bristol Myers-Squibb
|
| |
|
|
|
|
|
